Related references
Note: Only part of the references are listed.Chemotherapy Acts as an Adjuvant to Convert the Tumor Microenvironment into a Highly Permissive State for Vaccination-Induced Antitumor Immunity
Tae Heung Kang et al.
CANCER RESEARCH (2013)
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells
Dennis Lindau et al.
IMMUNOLOGY (2013)
Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines
Jurjen M. Ruben et al.
IMMUNOTHERAPY (2013)
Granulocytic myeloid-derived suppressor cells are cryosensitive and their frequency does not correlate with serum concentrations of colony-stimulating factors in head and neck cancer
Sokratis Trellakis et al.
INNATE IMMUNITY (2013)
Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine
Lionel Ades et al.
LEUKEMIA RESEARCH (2013)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity
Amir A. Toor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy
Katayoun Rezvani et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Dissection of T-cell Antigen Specificity in Human Melanoma
Rikke Sick Andersen et al.
CANCER RESEARCH (2012)
On the armament and appearances of human myeloid-derived suppressor cells
Isabel Poschke et al.
CLINICAL IMMUNOLOGY (2012)
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination
Junji Kawada et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples
Athanasios Kotsakis et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2012)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
Koji Kono et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers
Rikke Sick Andersen et al.
NATURE PROTOCOLS (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Combining immunotherapy and targeted therapies in cancer treatment
Matthew Vanneman et al.
NATURE REVIEWS CANCER (2012)
Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation
Benjamin J. Schmiedel et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
A TCR Targeting the HLA-A*0201-Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer
Nachimuthu Chinnasamy et al.
JOURNAL OF IMMUNOLOGY (2011)
Treating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells
Omar Al Ustwani et al.
LEUKEMIA RESEARCH (2011)
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
Oliver Goodyear et al.
BLOOD (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function
Jonas Stanke et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2010)
Equitoxic Doses of 5-Azacytidine and 5-Aza-2′Deoxycytidine Induce Diverse Immediate and Overlapping Heritable Changes in the Transcriptome
Xiangning Qiu et al.
PLOS ONE (2010)
CD49d provides access to untouched human Foxp3+ Treg free of contaminating effector cells
Markus Kleinewietfeld et al.
BLOOD (2009)
A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS
Ulrich Keilholz et al.
BLOOD (2009)
Treatment of Chronic Lymphocytic Leukemia with a Hypomethylating Agent Induces Expression of NXF2, an Immunogenic Cancer Testis Antigen
Jason A. Dubovsky et al.
CLINICAL CANCER RESEARCH (2009)
Targeting DNA Methylation
Jean-Pierre J. Issa et al.
CLINICAL CANCER RESEARCH (2009)
Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-beta 1
Hequan Li et al.
JOURNAL OF IMMUNOLOGY (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Demethylating treatment suppresses natural killer cell cytolytic activity
Xiao-ning Gao et al.
MOLECULAR IMMUNOLOGY (2009)
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers
Sine Reker Hadrup et al.
NATURE METHODS (2009)
Use of Epigenetic Modification to Induce FOXP3 Expression in Nalive T Cells
C. Moon et al.
TRANSPLANTATION PROCEEDINGS (2009)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11 and -B7
Arnold H. Bakker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
Michael Schmitt et al.
BLOOD (2008)
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
Shahram Y. Kordasti et al.
BLOOD (2007)
DNA methylation as a therapeutic target in cancer
Jean-Pierre J. Issa
CLINICAL CANCER RESEARCH (2007)
Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: Studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B
Lewis R. Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The role of leukemia-derived B7-H1 (PD-L1) in tumor-T-cell interactions in humans
Helmut Rainer Salih et al.
EXPERIMENTAL HEMATOLOGY (2006)
Design and use of conditional MHC class I ligands
M Toebes et al.
NATURE MEDICINE (2006)
Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes
G Marcucci et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Sensitive and viable identification of antigen-specific CD8+T cells by a flow cytometric assay for degranulation
MR Betts et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2003)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
